Clinical Trials
31 trialsMK-5684-004
Merck Sharp & Dohme LLC
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
PREDICT
Alliance for Clinical Trials in Oncology
OMAHA-003
Merck Sharp & Dohme LLC
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Inc
PRO-MIND
Ankara Etlik City Hospital
P300
Pathos AI, Inc.
DIVINE
Mayo Clinic
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Inc
Double-DARE
Bayer
SNARE
VA Office of Research and Development
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
KEYNOTE-365
Merck Sharp & Dohme LLC
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
University of California, San Francisco
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
University of Washington
APRE
Baylor College of Medicine
Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Mayo Clinic
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
ORIC Pharmaceuticals
ENABLE
Deventer Ziekenhuis
PARTOM
First Hospital of China Medical University
ProBio
Karolinska Institutet
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
GUNS
University of British Columbia
ANZadapt
Leiden University Medical Center
ECHOS
Santa Chiara Hospital
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School